IPERION (IPR) H2 2025 earnings summary

Executive summary

• Reported net loss of $455,683 for the year ended 31 March 2025, a significant improvement from the prior year's net loss of $822,259.

• Manufacturing plant expenses reduced to $150,000 from $500,000 due to discounts and research grants; further discounts secured for the next two years.

• Focus remains on product trials and converting these into long-term sales agreements for the Pathoglaze® antimicrobial product.

• Sufficient cash reserves to cover costs for the next 12 months based on forecasts with no sales.

Financial highlights

• Net loss for the year: $455,683 (2024: $822,259).

• Basic and diluted loss per share: (0.0885) cents (2024: (0.1597) cents).

• Cash and cash equivalents at year-end: $425,341 (2024: $168,647); term deposit fully withdrawn by year-end.

• Net tangible assets per share: 0.0677 cents (2024: 0.1562 cents).

• No revenue from product sales; interest income of $20,382.

Outlook and guidance

• Operations focused on marketing and securing long-term sales agreements following successful product trials.

• Manufacturing plant fixed fee fully discounted for FY26 and FY27; only cost of sales fees payable upon commencement of sales.

• License agreement performance targets extended by one year; must secure SGD150,000 revenue by 30 September 2026 and SGD1,000,000 by 30 September 2027.

• Company expects to manage known expenditure within current cash reserves through March 2027.